CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The primary endpoint is to assess the safety and tolerability of Cenderitide (CD-NP) with the
incidence of symptomatic hypotension being one of the key safety variables.